Description: Rocking
Scholar Rock receives fast track designation from the FDA for Apitegromab for the treatment of patients with spinal muscular atrophy. Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy – Builds on Priority Medicines (PRIME) designation recently granted by the European Medicines Agency (EMA) recognizing the unmet medical...
READ MORE Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy
Press release content from Accesswire. The AP news staff was not involved in its creation. ADVERTISEMENT Press release content from Accesswire. The AP news staff was not involved in its creation. Related topics Big Rock Partners Recommends All Stockholders Vote “FOR” ALL Proposals at Annual MeetingNEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp....